Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes

被引：0
|
作者：
Yuxin Mu
Xuezhi Hao
Puyuan Xing
Xingsheng Hu
Yan Wang
Teng Li
Jinyao Zhang
Ziyi Xu
Junling Li
机构：
[1] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology
[2] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词：
Non-small-cell lung cancer; Osimertinib; T790M; Resistance mechanism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2427 / 2433
页数：6
相关论文
共 50 条
  • [31] CLINICAL OUTCOMES IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER TREATED IN PHASE I CLINICAL TRIALS
    Janku, F.
    Gong, J.
    Garrido-Laguna, I.
    Parsons, H. A.
    Vaklavas, C.
    Kurzrock, R.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S86 - S86
  • [32] Cardiovascular events in eGFR-mutation non-small-cell lung cancer patients on osimertinib
    Mensah, Samuel Akaakole
    Ahmad, Syed
    Alruwaili, Waleed
    Raval, Rutu
    Gonuguntla, Karthik
    Patel, Brijesh
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024,
  • [33] Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
    Rodier, Thomas
    Puszkiel, Alicja
    Cardoso, Evelina
    Balakirouchenane, David
    Narjoz, Celine
    Arrondeau, Jennifer
    Fallet, Vincent
    Khoudour, Nihel
    Guidi, Monia
    Vidal, Michel
    Decleves, Xavier
    Csajka, Chantal
    Alexandre, Jerome
    Cadranel, Jacques
    Fabre, Elizabeth
    Wislez, Marie
    Goldwasser, Francois
    Blanchet, Benoit
    PHARMACEUTICS, 2022, 14 (09)
  • [34] Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
    Paz-Ares, Luis
    Soulieres, Denis
    Melezinek, Ivan
    Moecks, Joachim
    Keil, Lorenz
    Mok, Tony
    Rosell, Rafael
    Klughammer, Barbara
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (1-2) : 51 - 69
  • [35] Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
    Manan P. Shah
    Joel W. Neal
    Drugs, 2022, 82 : 649 - 662
  • [36] Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
    Shah, Manan P.
    Neal, Joel W.
    DRUGS, 2022, 82 (06) : 649 - 662
  • [37] Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Planchard, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1780 - 1782
  • [38] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Tsuboi, Masahiro
    He, Jie
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Kato, Terufumi
    Vu, Huu-Vinh
    Lu, Shun
    Lee, Kye-Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Hodge, Rachel
    Atasoy, Ajlan
    Rukazenkov, Yuri
    Herbst, Roy S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1711 - 1723
  • [39] Response to erlotinib and bevacizumab combination therapy after acquired resistance to osimertinib in patients with non-small cell lung cancer
    Satoh, Hiroaki
    Kagohashi, Katsunori
    ANTI-CANCER DRUGS, 2022, 33 (03) : 320 - 322
  • [40] Multidrug resistance in non-small-cell lung cancer
    Scagliotti, GV
    Novello, S
    Selvaggi, G
    ANNALS OF ONCOLOGY, 1999, 10 : 83 - 86
12345